Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: Effect on lung function, health status and sputum

被引:88
作者
Daviskas, E
Anderson, SD
Gomes, K
Briffa, P
Cochrane, B
Chan, HK
Young, IH
Rubin, BK
机构
[1] Royal Prince Alfred Hosp, Dept Resp Med, Camperdown, NSW 2050, Australia
[2] Univ Sydney, Dept Pharm, Sydney, NSW 2006, Australia
[3] Wake Forest Univ, Sch Med, Dept Pediat, Winston Salem, NC 27109 USA
关键词
bronchiectasis; cough; health-related quality of life; mannitol; sputum properties;
D O I
10.1111/j.1440-1843.2005.00659.x
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Objective: Inhaled mannitol increases mucus clearance in patients with bronchiectasis by an unclear mechanism. The effect of mannitol on lung function, health status and sputum properties was investigated. Methodology: Nine patients with bronchiectasis inhaled 400 mg of mannitol once daily for 12 days. Health status was assessed using the St George's Respiratory Questionnaire (SGRQ). Sputum was analysed for viscosity, elasticity, spinnability, surface tension, contact angle, solids, mucociliary transportability (MCTR) on a frog palate, and cough transportability (CTR) on a simulated cough machine. Results: Lung function was unchanged with treatment (baseline FEV1 82.0 +/- 16.2%) apart from an improvement in FEF from 85.4 +/- 13% (baseline) to 90.7 +/- 14.4% (P < 0.05; 12th treatment; visit 7). The total SGRQ score (mean SD) of 49.3 +/- 13.8 at baseline, decreased by 12.4 +/- 10.2 (P < 0.01; visit 7) and 10.1 +/- 9.4 units (P < 0.02) 6-10 days after treatment cessation. The baseline subscores for symptoms (72.9 +/- 11.8), activity (44.7 +/- 20.9) and impact (44.4 +/- 14.3) were reduced by 0.8 +/- 9.1 (P > 0.7), 8.4 +/- 16.0 (P > 0.1) and 19.2 +/- 13.7 (P < 0.005) units, respectively (visit 7). Mannitol reduced the baseline (mean SE) surface tension from 94.5 1.4 to 84.7 2.1 mN/rn (P < 0.0001), contact angle from 51.1 +/- 2.8 to 33.2 +/- 2.4 degrees (P < 0.0001), spinnability from 11.6 +/- 0.4 to 10.0 +/- 0.2 mm (P < 0.005), and solids from 5.7 +/- 0.4 to 4.3 +/- 0.7% (P < 0.02), acutely (visit 7). Viscosity, elasticity and MCTR did not change significantly, while CTR was increased from 25.8 +/- 1.0 to 34.1 +/- 2.7 mm (P < 0.003). Conclusion: Mannitol significantly improved the health status over 12 days and this improvement was maintained for 6-10 days after cessation of treatment. In addition, mannitol reduced the tenacity, increased the hydration of mucus acutely and improved cough clearability in patients with bronchiectasis.
引用
收藏
页码:46 / 56
页数:11
相关论文
共 31 条
[1]   Ring distraction technique for measuring surface tension of sputum: Relationship to sputum clearability [J].
Albers, GM ;
Tomkiewicz, RP ;
May, MK ;
Ramirez, OE ;
Rubin, BK .
JOURNAL OF APPLIED PHYSIOLOGY, 1996, 81 (06) :2690-2695
[2]   A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol [J].
Anderson, SD ;
Brannan, J ;
Spring, J ;
Spalding, N ;
Rodwell, LT ;
Chan, K ;
Gonda, I ;
Walsh, A ;
Clark, AR .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 156 (03) :758-765
[3]   IMPAIRED TRACHEOBRONCHIAL CLEARANCE IN BRONCHIECTASIS [J].
CURRIE, DC ;
PAVIA, D ;
AGNEW, JE ;
LOPEZVIDRIERO, MT ;
DIAMOND, PD ;
COLE, PJ ;
CLARKE, SW .
THORAX, 1987, 42 (02) :126-130
[4]   Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis [J].
Daviskas, E ;
Anderson, SD ;
Eberl, S ;
Chan, HK ;
Bautovich, G .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (06) :1843-1848
[5]   Inhalation of dry-powder mannitol increases mucociliary clearance [J].
Daviskas, E ;
Anderson, SD ;
Brannan, JD ;
Chan, HK ;
Eberl, S ;
Bautovich, G .
EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (11) :2449-2454
[6]   The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis [J].
Daviskas, E ;
Anderson, SD ;
Eberl, S ;
Chan, HK ;
Young, IH .
CHEST, 2001, 119 (02) :414-421
[7]   Revisited physicochemical and transport properties of respiratory mucus in genotyped cystic fibrosis patients [J].
Deneuville, E ;
PerrotMinot, C ;
Pennaforte, F ;
Roussey, M ;
Zahm, JM ;
Clavel, C ;
Puchelle, E ;
deBentzmann, S .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 156 (01) :166-172
[8]   A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol [J].
Donohue, JF ;
van Noord, JA ;
Bateman, ED ;
Langley, SJ ;
Lee, A ;
Witek, TJ ;
Kesten, S ;
Towse, L .
CHEST, 2002, 122 (01) :47-55
[9]   Improved clearability of cystic fibrosis sputum with dextran treatment in vitro [J].
Feng, W ;
Garrett, H ;
Speert, DP ;
King, M .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (03) :710-714
[10]   Quality of life assessment after patient education in a randomized controlled study on asthma and chronic obstructive pulmonary disease [J].
Gallefoss, F ;
Bakke, PS ;
Kjærsgaard, P .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) :812-817